I
Ignota Labs
Using cutting-edge AI algorithms to predict toxic endpoints, earlier in the drug discovery process
About Ignota Labs
Ignota Labs is a pioneering startup operating in the pharmaceutical and biotechnology sector, leveraging the power of artificial intelligence (AI) to enhance drug discovery processes. The company's proprietary AI platform, developed by a team of expert scientists, machine learning engineers, and toxicologists, is designed to predict, understand, and solve safety problems in drug discovery. This platform is a game-changer in the industry, offering a predictive toxicology suite that can revolutionize drug discovery pipelines.
Ignota Labs primarily serves clients in the pharmaceutical and biotech industries, providing them with advanced AI solutions to streamline their drug discovery processes and mitigate safety failures. The company's business model is based on partnerships with these clients, offering them access to their cutting-edge predictive toxicology suite. This suite is a bespoke solution that can be tailored to the specific needs of each client, ensuring optimal results and efficiency.
The company generates revenue through these partnerships, charging clients for access to their AI platform and the predictive toxicology suite. This approach allows Ignota Labs to provide a high-value service that can significantly enhance the drug discovery process, while also generating a steady stream of revenue.
In summary, Ignota Labs is a forward-thinking startup that is harnessing the power of AI to revolutionize drug discovery, offering a unique service that can significantly enhance safety and efficiency in the pharmaceutical and biotech industries.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- 22
- Open positions
- 2
- Dealroom signal
- 84.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Sustainable Development Goals, Tech for Biotech and Pharma, Climate Tech, AI Drug Discovery
- Technology
- Artificial Intelligence, Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Feb 2025 | $6.9M | $28M | AIX Ventures · Blue Wire Capital · Gaingels · Montage Ventures | ↗ |
| GRANT✓Other financing | Dec 2024 | $98K | — | UK Research and Innovation | — |
Growth signals
Latest recorded traffic for Ignota Labs is 3.3K monthly website visits, up 17.9% over the last three months. Ignota Labs's team grew 10% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Sustainable Ventures
UK Research and Innovation
AIX Ventures
Montage Ventures
Blue Wire Capital
Gaingels
Modi Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ignota Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ignota Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.